NuCana (NASDAQ:NCNA) Trading 5.8% Higher – Should You Buy?

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s share price traded up 5.8% on Thursday . The stock traded as high as $1.6667 and last traded at $1.63. Approximately 18,351 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 54,613 shares. The stock had previously closed at $1.54.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

NuCana Trading Up 5.8%

The stock has a market cap of $48,900.00, a price-to-earnings ratio of -0.01 and a beta of 1.79. The stock’s 50 day moving average is $2.08 and its two-hundred day moving average is $3.33.

Hedge Funds Weigh In On NuCana

A hedge fund recently raised its stake in NuCana stock. FNY Investment Advisers LLC grew its position in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,000 shares of the company’s stock after buying an additional 6,774 shares during the quarter. FNY Investment Advisers LLC owned 33.33% of NuCana worth $36,000 as of its most recent filing with the SEC. 44.00% of the stock is currently owned by institutional investors and hedge funds.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.